Detail page

Knowledge Web

Person

Marion Tina van Mackelenbergh (1981-)

Onkologin

Name	Marion Tina van Mackelenbergh
Time	1981- (Date of birth and death)
Place	Kiel (Geburtsort) Kiel (Wirkungsort) Deutschland
Academic degree	Dr. med.
Profession	Onkologin (characteristic profession)
Variant	Marion Weigel (früherer Name) Marion Tina Weigel (früherer Name) Marion van Mackelenbergh Marion T. Van Mackelenbergh Marion Van Mackelenbergh Marion T. VanMackelenbergh Marion T. van Mackelenbergh Marion T. Mackelenbergh
Related	Klinik für Gynäkologie und Geburtshilfe (Frauenheilkunde) Universitätsklinikum Schleswig-Holstein
Further information	Diss. Medizinische Fakultät der Univ. Kiel, Habil.-Schr., Medizinische Fakultät der Univ. Kiel
Record type	Person
GND-Identifier	133221520
Record ID	133221520
Involved in show all ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment—A New Concept Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept Characterization of hormone receptor and HER2 status in breast cancer using mass spectrometry imaging Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer Retrospektive Studie zur Entwicklung der Diagnostik und Therapie des Endometriumkarzinoms von 1998-2014 an der Klinik für Gynäkologie und Geburtshilfe des UKSH am Campus Kiel Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials Untersuchungen zur Relevanz des platelet-derived growth factor (PDGF) Signalweges beim Mamma- und Ovarialkarzinom Untersuchungen zum Einfluss des Tyrosinkinaserezeptorinhibitors Imatinib-Mesylat auf das Wachstum und den PDGFR-β-Signalweg [PDGFR-beta-Signalweg] von Mammakarzinomzelllinien

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Marion Tina van Mackelenbergh (1981-)

ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment—A New Concept

Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept

Characterization of hormone receptor and HER2 status in breast cancer using mass spectrometry imaging

Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging

DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status

DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status

High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer

Retrospektive Studie zur Entwicklung der Diagnostik und Therapie des Endometriumkarzinoms von 1998-2014 an der Klinik für Gynäkologie und Geburtshilfe des UKSH am Campus Kiel

Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials

Untersuchungen zur Relevanz des platelet-derived growth factor (PDGF) Signalweges beim Mamma- und Ovarialkarzinom

Untersuchungen zum Einfluss des Tyrosinkinaserezeptorinhibitors Imatinib-Mesylat auf das Wachstum und den PDGFR-β-Signalweg [PDGFR-beta-Signalweg] von Mammakarzinomzelllinien